Eli Lilly and Company (LLY)

Pharmaceuticals, 50,000 people, 54% in the U.S.. Read October 2, 2026 from the annual report for the period ending December 31, 2025, filed February 12, 2026. Ranked 30 of the 36 Healthcare companies read so far, by the share within reach now.

The filing states the total, the count outside the U.S. and the research count, nothing else by kind of work, so one pharmaceutical pattern carries the whole workforce.

The figures on this page come from the company's own annual report and from BLS staffing patterns for its industries, never from a roster. They are estimates with a stated method. Nothing here says what the company will do: within reach is not a forecast of jobs lost or of savings.

What follows from the reading

Share of working time within reach of AI, on the long-run pace at four in five: 18% now, 33% at the end of 2027, 41% at the end of 2028, 44% at the end of 2030. By the patterns, the work is about 44% desk work, 14% people work and 42% body work. These are the site's industry estimates weighted by the shares below: estimates with a stated method and range, not a forecast of what the company will do. By the same patterns, at the end of 2028 about 56% of the working time stays with people (conversation, in-person and hands-on work), 37% becomes checking a model's work and 4% could be handed over with lighter checks, from the industries' own figures, not the company's roles.

Headcount

50,000 employees as of December 31, 2025 (stated). About 27,000 of 50,000 outside the U.S., so about 23,000 in the U.S.

The filing: “At the end of 2025, we employed approximately 50,000 people, including approximately 27,000 employees outside the U.S.”

The workforce as industry patterns

What the filing says about the workforce: About 50,000 people, about 27,000 outside the U.S.; about 12,000 in pharmaceutical research and development, including physicians, scientists with graduate degrees and technical personnel.

Companies read with the same leading pattern

Other companies whose largest staffing pattern is also Pharmaceutical and Medicine Manufacturing, largest first, each read from its own annual report. Within reach now and at the end of 2028, long-run pace, four in five.

• Johnson & Johnson (JNJ, 140,800 employees)18% now, 39% by 2028
• Thermo Fisher Scientific Inc. (TMO, 125,000 employees)19% now, 49% by 2028
• Merck & Co., Inc. (MRK, 75,000 employees)18% now, 41% by 2028
• Pfizer Inc. (PFE, 75,000 employees)18% now, 41% by 2028
• AbbVie Inc. (ABBV, 57,000 employees)18% now, 41% by 2028

What the filing says about AI

20 sentences in the filing name AI. Twenty sentences: AI vendors among the third parties the company has expanded relationships with, and the risk that its use of AI or other emerging technologies could adversely impact it.

• “The following include some but not all of the factors that could cause actual results or events to differ from those anticipated: the significant costs and uncertainties in the pharmaceutical research and development process, including with respect to the timing and process of obtaining regulatory approvals and the ability of the company's clinical trials to meet expectations; the impact and un...”
• “To support anticipated demand for our current and prospective products and further other business initiatives, we have expanded relationships with contract manufacturing organizations, entities supporting consumer directed access channels, artificial intelligence vendors, and other third parties in recent periods.”
• “Our use of artificial intelligence (AI) or other emerging technologies could adversely impact us.”
• “We deploy AI and other emerging technologies in various facets of our operations and we continue to explore the development and use of AI technologies.”
• “We have also entered into, and may continue to enter into, partnerships and collaborations relating to the use of AI technology to aid in drug discovery and other efforts.”

Its annual reports, year by year

Sentences naming AI in each annual report, counted by one rule, beside the median report in the Index that year. Each count links its filing. Every company, by year and sector

• Fiscal 20210median 0
• Fiscal 20220median 0
• Fiscal 202314median 1
• Fiscal 202416median 4
• Fiscal 202520median 10

Headcount by filing year

As reported in each year's annual report, with the filing. A year marked not read had no figure the reading could take from the report's text.

Limits of this reading

• The 12,000 in research and development are a counted function, recorded in the notes, not a pattern split (like the engineers at Lockheed Martin).

Source: the company's annual report on EDGAR, accession 0000059478-26-000013, the filing. Read by Claude Fable 5.1 under rubric version 1, by the method. A company can write to info@stratussc.com to have its reading checked against its filing.